Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:27:00.522Z.
Calculation as of: 2026-10-06T16:27:00.522Z.
Quote observation: 2026-10-06T16:25:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$5.95B
EV/EBITDA Ratio
45.02x
TTM Avg
617.82x
3Y Avg
545.60x
5Y Avg
321.06x
Market Cap
$5.87B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.76B
EV/EBITDA Ratio
54.78x
TTM Avg
88.38x
3Y Avg
133.43x
5Y Avg
103.02x
Market Cap
$6.33B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.54B
EV/EBITDA Ratio
30.81x
TTM Avg
33.01x
3Y Avg
33.01x
5Y Avg
33.01x
Market Cap
$6.51B
EV/EBITDA Ratio
16.99x
TTM Avg
14.43x
3Y Avg
16.48x
5Y Avg
56.22x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $5.94B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 45.02x | 617.82x | 545.60x | 321.06x |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.87B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.76B | 54.78x | 88.38x | 133.43x | 103.02x |
| CG Oncology Inc. (CGON)vs › | $5.71B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.33B | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | 30.81x | 33.01x | 33.01x | 33.01x |
| RadNet, Inc. (RDNT)vs › | $5.52B | 21.68x | 24.95x | 22.12x | 17.84x |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 16.99x | 14.43x | 16.48x | 56.22x |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 15.36x | 12.72x | 11.11x | 13.30x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
